Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in substantial reductions in body weight.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 389; no. 6; pp. 514 - 526
Main Authors:	Jastreboff, Ania M., Kaplan, Lee M., Frías, Juan P., Wu, Qiwei, Du, Yu, Gurbuz, Sirel, Coskun, Tamer, Haupt, Axel, Milicevic, Zvonko, Hartman, Mark L.
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 10-08-2023
Subjects:	Agonists Body weight Clinical Medicine Clinical Medicine General Confidence intervals Diabetes Diet Drug therapy Endocrinology Gastroenterology GIP protein Glucagon Glucagon-like peptide 1 Heart rate Nutrition Obesity Peptides Placebos Statistical analysis Weight control United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in substantial reductions in body weight.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2301972